How many stocks are there of Agenus?
The current number of stocks of Agenus is 17.89 M undefined.
Agenus Stocks 2024
Agenus Stocks
17.89 M
Ticker
AGEN
ISIN
US00847G7051
WKN
A1JLKZ
In 2024, Agenus had 17.89 M outstanding stocks, a 0% change from the 17.89 M stocks in the previous year.
The Agenus Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 17.89 |
| 2028e | 17.89 |
| 2027e | 17.89 |
| 2026e | 17.89 |
| 2025e | 17.89 |
| 2024e | 17.89 |
| 2023 | 17.89 |
| 2022 | 14.09 |
| 2021 | 11.45 |
| 2020 | 8.63 |
| 2019 | 6.75 |
| 2018 | 5.54 |
| 2017 | 4.92 |
| 2016 | 4.35 |
| 2015 | 3.91 |
| 2014 | 2.99 |
| 2013 | 1.49 |
| 2012 | 1.18 |
| 2011 | 1 |
| 2010 | 0.81 |
| 2009 | 0.66 |
| 2008 | 0.53 |
| 2007 | 0.39 |
| 2006 | 0.38 |
| 2005 | 0.38 |
| 2004 | 0.37 |
Agenus shares outstanding US00847G7051 · A1JLKZ
The number of shares was Agenus in 2023 — This indicates how many shares 17.894 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Agenus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Agenus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Agenus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Agenus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 372,000 Aktien |
| 2005 | 380,000 Aktien |
| 2006 | 382,000 Aktien |
| 2007 | 388,000 Aktien |
| 2008 | 527,000 Aktien |
| 2009 | 658,000 Aktien |
| 2010 | 805,000 Aktien |
| 2011 | 995,000 Aktien |
| 2012 | 1.18 M Aktien |
| 2013 | 1.49 M Aktien |
| 2014 | 2.99 M Aktien |
| 2015 | 3.91 M Aktien |
| 2016 | 4.35 M Aktien |
| 2017 | 4.92 M Aktien |
| 2018 | 5.54 M Aktien |
| 2019 | 6.75 M Aktien |
| 2020 | 8.63 M Aktien |
| 2021 | 11.45 M Aktien |
| 2022 | 14.09 M Aktien |
| 2023 | 17.89 M Aktien |
| 2024e | 17.89 M Aktien |
| 2025e | 17.89 M Aktien |
| 2026e | 17.89 M Aktien |
| 2027e | 17.89 M Aktien |
| 2028e | 17.89 M Aktien |
| 2029e | 17.89 M Aktien |
Agenus Aktienanalyse
What does Agenus do?
Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Agenus's Shares Outstanding
Agenus's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Agenus’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Agenus’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Agenus’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Agenus stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Agenus are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Agenus evolved in recent years?
The number of shares of Agenus has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Agenus as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Agenus?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Agenus pay?
Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.
What is the dividend yield of Agenus?
The current dividend yield of Agenus is .
When does Agenus pay dividends?
Agenus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Agenus?
Agenus paid dividends every year for the past 0 years.
What is the dividend of Agenus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Agenus located?
Agenus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Agenus from 8/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Agenus pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Agenus in the year 2023?
In the year 2023, Agenus distributed 0 USD as dividends.
In which currency does Agenus pay out the dividend?
The dividends of Agenus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Agenus
Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
